Categories
RPG Life Sciences Limited — Updates, 29-04-2026: Press Release
29-04-2026 · 08:44 pm
RPG Life Sciences posted robust Q4 results: Revenue up 23.6% to Rs 176.9 Cr; EBITDA margin 25.6%. FY revenue rose 8.3% to Rs 707.5 Cr. Strong Domestic Formulations and API growth drove performance. The board announced a 300% dividend (Rs 24/share).
No comments yet. Be the first to comment!